Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Acquires 72,700 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc bought 72,700 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $1.39 per share, with a total value of $101,053.00. Following the transaction, the chief executive officer owned 976,121 shares in the company, valued at approximately $1,356,808.19. This represents a 8.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

MAIA Biotechnology Stock Down 6.5%

Shares of MAIA stock opened at $1.30 on Tuesday. MAIA Biotechnology, Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $3.19. The firm’s 50 day moving average price is $1.32 and its two-hundred day moving average price is $1.52. The stock has a market cap of $79.04 million, a price-to-earnings ratio of -1.94 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, equities analysts forecast that MAIA Biotechnology, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares during the period. Marshall Wace LLP acquired a new stake in shares of MAIA Biotechnology in the second quarter valued at about $29,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at about $52,000. Ritholtz Wealth Management acquired a new position in MAIA Biotechnology during the 4th quarter worth approximately $35,000. Finally, Centric Wealth Management lifted its position in MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after acquiring an additional 11,500 shares in the last quarter. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.